Advertisement
Screener

PFIZER INC (PFE) Increase (Decrease) in Operating Capital

2.8 / 5 stars · 68/120 Roast Me

PFIZER INC Increase (Decrease) in Operating Capital

PFIZER INC (PFE) reported Increase (Decrease) in Operating Capital of $3.55 billion for the 6-month period ending 2026-06-28, per its 10-Q filed 2026-08-04.

Financial Statements › Cash Flow › Operating Activities

us-gaap:IncreaseDecreaseInOperatingCapital · last filed 2026-08-04

  • PFIZER INC increase (decrease) in operating capital for the quarter ending 2026-06-28 was $1.82B, a 63.60% decline year-over-year.
  • PFIZER INC increase (decrease) in operating capital for the quarter ending 2026-03-29 was $1.73B, a 9.74% decline year-over-year.
  • PFIZER INC increase (decrease) in operating capital for the quarter ending 2025-09-28 was $36.00M.
  • PFIZER INC increase (decrease) in operating capital for the quarter ending 2025-06-29 was $4.99B, a 41.13% increase year-over-year.
Period endIncrease (Decrease) in Operating Capital 3 monthIncrease (Decrease) in Operating Capital 3 month as first filedIncrease (Decrease) in Operating Capital 6 monthIncrease (Decrease) in Operating Capital 6 month as first filedIncrease (Decrease) in Operating Capital 9 monthIncrease (Decrease) in Operating Capital 9 month as first filed
2026-06-28$1.82B
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$3.55B
10-Q · filed 2026-08-04
2026-03-29$1.73B
10-Q · filed 2026-05-05
2025-09-28$36.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$5.03B
derived: sum of 2 quarters · filed 2026-08-04
$6.94B
10-Q · filed 2025-11-04
2025-06-29$4.99B
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-04
$6.91B
10-Q · filed 2026-08-04
2025-03-30$1.92B
10-Q · filed 2026-05-05
2024-09-29-$879.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04
$2.66B
derived: sum of 2 quarters · filed 2025-11-04
$5.99B
10-Q · filed 2025-11-04
2024-06-30$3.54B
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05
$6.87B
10-Q · filed 2025-08-05
2024-03-31$3.34B
10-Q · filed 2025-05-05
2023-10-01$1.20B
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04
$5.12B
derived: sum of 2 quarters · filed 2024-11-04
$10.62B
10-Q · filed 2024-11-04
2023-07-02$3.92B
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05
$9.42B
10-Q · filed 2024-08-05
2023-04-02$5.51B
10-Q · filed 2024-05-08
2022-10-02$4.58B
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08
$7.35B
derived: sum of 2 quarters · filed 2023-11-08
$8.08B
10-Q · filed 2023-11-08
$7.61B
10-Q · filed 2022-11-09
2022-07-03$2.77B
derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09
$3.50B
10-Q · filed 2023-08-09
2022-04-03$730.00M
10-Q · filed 2023-05-10
2021-10-03-$6.76B
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09
-$12.15B
derived: sum of 2 quarters · filed 2022-11-09
-$10.87B
10-Q · filed 2022-11-09
-$10.82B
10-Q · filed 2021-11-12
2021-07-04-$5.38B
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10
-$4.10B
10-Q · filed 2022-08-10
-$4.40B
10-Q · filed 2021-08-12
2021-04-04$1.28B
10-Q · filed 2022-05-11
$1.33B
10-Q · filed 2021-05-13
2020-09-27$800.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-12
$1.34B
derived: sum of 2 quarters · filed 2021-11-12
$2.86B
10-Q · filed 2021-11-12
$3.08B
10-Q · filed 2020-11-05
2020-06-28$541.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12
$2.06B
10-Q · filed 2021-08-12
$2.23B
10-Q · filed 2020-08-06
2020-03-29$1.51B
10-Q · filed 2021-05-13
$1.58B
10-Q · filed 2020-05-07
2019-09-29-$1.48B
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$2.07B
derived: sum of 2 quarters · filed 2020-11-05
$5.57B
10-Q · filed 2020-11-05
2019-06-30$3.55B
derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06
$7.05B
10-Q · filed 2020-08-06
2019-03-31$3.50B
10-Q · filed 2020-05-07
2018-09-30-$809.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-07
-$274.00M
derived: sum of 2 quarters · filed 2019-11-07
$2.44B
10-Q · filed 2019-11-07
2018-07-01$535.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-08
$3.25B
10-Q · filed 2019-08-08
2018-04-01$2.71B
10-Q · filed 2019-05-09
2017-10-01-$228.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08
$1.40B
derived: sum of 2 quarters · filed 2018-11-08
$3.62B
10-Q · filed 2018-11-08
$3.64B
10-Q · filed 2017-11-09
2017-07-02$1.63B
derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09
$3.84B
10-Q · filed 2018-08-09
$3.85B
10-Q · filed 2017-08-10
2017-04-02$2.22B
10-Q · filed 2018-05-10
$2.23B
10-Q · filed 2017-05-11
2016-10-02-$1.60B
derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09
-$543.00M
derived: sum of 2 quarters · filed 2017-11-09
$1.58B
10-Q · filed 2017-11-09
$1.72B
10-Q · filed 2016-11-10
2016-07-03$1.06B
derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-10
$3.18B
10-Q · filed 2017-08-10
$3.32B
10-Q · filed 2016-08-11
2016-04-03$2.13B
10-Q · filed 2017-05-11
$2.26B
10-Q · filed 2016-05-12
2015-09-27-$582.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-10
-$586.00M
derived: sum of 2 quarters · filed 2016-11-10
$1.30B
10-Q · filed 2016-11-10
$1.29B
10-Q · filed 2015-11-05
2015-06-28-$4.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-11
$1.88B
10-Q · filed 2016-08-11
$1.87B
10-Q · filed 2015-08-06
2015-03-29$1.88B
10-Q · filed 2016-05-12
$1.88B
10-Q · filed 2015-05-07
2014-09-28-$430.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-05
$428.00M
derived: sum of 2 quarters · filed 2015-11-05
$1.52B
10-Q · filed 2015-11-05
2014-06-29$858.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-06
$1.95B
10-Q · filed 2015-08-06
2014-03-30$1.09B
10-Q · filed 2015-05-07
2013-09-29-$715.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-06
$1.42B
derived: sum of 2 quarters · filed 2014-11-06
$4.75B
10-Q · filed 2014-11-06
$4.31B
10-Q · filed 2013-11-08
2013-06-30$2.14B
derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07
$5.46B
10-Q · filed 2014-08-07
$5.27B
10-Q · filed 2013-08-09
2013-03-31$3.33B
10-Q · filed 2014-05-08
$3.39B
10-Q · filed 2013-05-10
2012-09-30$417.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-08
$1.81B
derived: sum of 2 quarters · filed 2013-11-08
$3.34B
10-Q · filed 2013-11-08
$3.51B
10-Q · filed 2012-11-09
2012-07-01$1.39B
derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09
$2.92B
10-Q · filed 2013-08-09
$3.04B
10-Q · filed 2012-08-09
2012-04-01$1.53B
10-Q · filed 2013-05-10
$1.56B
10-Q · filed 2012-05-10
2011-10-02$361.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-09
$624.00M
derived: sum of 2 quarters · filed 2012-11-09
$102.00M
10-Q · filed 2012-11-09
$326.00M
10-Q · filed 2011-11-10
2011-07-03$263.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-09
-$259.00M
10-Q · filed 2012-08-09
-$187.00M
10-Q · filed 2011-08-11
2011-04-03-$522.00M
10-Q · filed 2012-05-10
2010-10-03-$2.66B
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-10
-$1.70B
derived: sum of 2 quarters · filed 2011-11-10
$10.51B
10-Q · filed 2011-11-10
2010-07-04$959.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-12
$13.17B
10-Q · filed 2011-08-11
2010-04-04$11.98B
10-Q · filed 2011-05-12
$11.82B
10-Q · filed 2010-05-13
2009-09-27$593.00M
derived: 10-Q 9 month − 10-Q 6 month · filed 2010-11-12
-$59.00M
derived: sum of 2 quarters · filed 2010-11-12
$840.00M
10-Q · filed 2010-11-12
$522.00M
10-Q · filed 2009-11-05
2009-06-28-$652.00M
derived: 10-Q 6 month − 10-Q 3 month · filed 2010-08-12
$247.00M
10-Q · filed 2010-08-12
-$247.00M
10-Q · filed 2009-08-06
2009-03-29$899.00M
10-Q · filed 2010-05-13
2008-09-28$3.17B
derived: 10-Q 9 month − 10-Q 6 month · filed 2009-11-05
$1.54B
10-Q · filed 2009-11-05
2008-06-29-$1.63B
10-Q · filed 2009-08-06

Similar stocks

Stock NameCountryMarket CapPE Ratio
ABBOTT LABORATORIES (ABT)United States$176.045B28.47
VERTEX PHARMACEUTICALS INC / MA (VRTX)United States$132.481B28.56
BRISTOL MYERS SQUIBB CO (BMY)United States$125.637B12.67
REGENERON PHARMACEUTICALS, INC. (REGN)United States$74.751B21.53
ALNYLAM PHARMACEUTICALS, INC. (ALNY)United States$33.420B54.94
Zoetis Inc. (ZTS)United States$29.045B11.38
INSMED Inc (INSM)United States$26.566B-26.60
Roivant Sciences Ltd. (ROIV)$26.105B-96.08
Royalty Pharma plc (RPRX)United States$22.628B
UNITED THERAPEUTICS Corp (UTHR)United States$20.249B17.64